Cell-based immunotherapy in oesophageal cancer

J Drug Target. 2025 Aug;33(7):1114-1124. doi: 10.1080/1061186X.2025.2477077. Epub 2025 Mar 17.

Abstract

Oesophageal cancer (EC) is among the most common illnesses globally, and its prognosis is unfavourable. Surgery, radiotherapy and chemotherapy are the primary therapy options for EC. Despite the occasional efficacy of these traditional treatment modalities, individuals with EC remain at a significant risk for local recurrence and metastasis. Consequently, innovative and efficacious medicines are required. In recent decades, clinical practice has effectively implemented cell therapy, which includes both stem cell and non-stem cell-based approaches, as an innovative tumour treatment, offering renewed hope to patients with oesophageal squamous cell carcinoma (ESCC). This paper examines the theoretical framework and contemporary advancements in cell treatment for individuals with EC. We further described current clinical studies and summarised essential data related to survival and safety assessments.

Keywords: CAR-T; Oesophageal cancer; cell therapy; macrophage-based cell therapies; stem cell therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell- and Tissue-Based Therapy* / methods
  • Esophageal Neoplasms* / immunology
  • Esophageal Neoplasms* / therapy
  • Esophageal Squamous Cell Carcinoma* / immunology
  • Esophageal Squamous Cell Carcinoma* / therapy
  • Humans
  • Immunotherapy* / methods